AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement

(Hong Kong, 10 April 2026) - AilsynBio, an AI-driven drug discovery company, held a Project Cooperation Agreement Signing Ceremony today at the Hong Kong Science Park, announcing a comprehensive project cooperation agreement with Dong-E-E-Jiao Co., Ltd. (000423.SZ). This partnership marks a profound cross-sector integration of Artificial Intelligence (AI) and traditional medicine, aiming to empower biopharmaceutical innovation through technological means.

The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP), and The University of Hong Kong (HKU), to witness this significant milestone.

Derek Chim, Head of Startup Ecosystem and Development of HKSTP, said: “This cooperation reflects exactly what Incu-Bio was built to achieve — nurturing startups that partner with global leaders like Dong-E-E-Jiao. It’s proof that the ecosystem works and that our approach delivers real results. It also demonstrates HKSTP’s growing focus on biotech innovation and AI, which now spans the entire healthcare value chain. We congratulate both teams on this achievement and look forward to seeing more collaborations like this emerge from Hong Kong’s vibrant innovation community.”

Dr Bo Chen, Chief Scientist of China Resources Pharmaceutical, noted: “This collaboration with Dong-E-E-Jiao and AilsynBio is an important practice for China Resources Pharmaceutical in promoting the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of 'AI + TCM' between Mainland China and Hong Kong. We look forward to integrating scientific research and industrial resources from both regions to solve the challenges of TCM's mechanisms of action and provide an innovative path for TCM to evolve from empirical medicine to evidence-based medicine.”

Liang Zheng, Vice President of Dong-E-E-Jiao, stated: “As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women’s health, helping Dong-E-E-Jiao accelerate into a new stage of ‘reshaping TCM wisdom through technological innovation.’”

Pierre Wang, Managing Director of HKU Versitech Limited, stated: “HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical Group Limited subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of world-class academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company’s rapid international growth and its mission to scale cutting-edge biotechnology globally.”

Looking ahead, the two parties will focus on three key collaborative directions:

• Advancing AI-driven innovation: Leveraging AilsynBio’s AI drug discovery platform to accelerate biopharmaceutical R&D processes.
• Launching specialized research: Engaging in in-depth cooperation on the "Premature Ovarian Insufficiency (POI)" research project.
• Promoting cross-border fusion: Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry.

During the ceremony, AilsynBio and Dong-E-E-Jiao signed the agreement on behalf of their respective organizations. The signing was witnessed by Dr Bo Chen, Chief Scientist of China Resources Pharmaceutical; Eric Or, Chief Ecosystem Development Officer of HKSTP; and Pierre Wang, Managing Director of HKU Versitech.

AilsynBio stated that this cooperation is not only a combination of technologies but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.